COVID-19 Updates
IWK & COVID-19: Latest Updates
Hotline: 1-902-233-3495
IWK

1.902.470.8888

1.888.470.5888

Emergency: 911
Telecare: 811
Poison: 1-800-565-8161
5850/5980 University Ave., Halifax, NS B3K 6R8

Adverse Incident Reporting : Palivizumab (Synagis®)

Any suspected adverse incident can be reported to the Canadian Vigilance Program at:

Canadian Vigilance Program (CVP)
Marketed Health Products Directorate
HEALTH CANADA
Address Locator: 1908C
OTTAWA, Ontario, K1A 0K9
Tel: (613) 957-0337 or Fax: (613) 957-0335
Toll free for consumers and health professionals:
Tel: 866 234-2345, Fax: 866 678-6789 hc.canada.vigilance.sc@canada.ca

The AR Reporting Form and the AR Guidelines can be found on the Health Canada web site or in The Canadian Compendium of Pharmaceuticals and Specialties.

The IWK Health Centre will request a report from Health Canada on any adverse reactions within Canada during the previous RSV season and review this information with the palivizumab working group annually.